Paclitaxel is under clinical development by Fulgent Pharma and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Paclitaxel LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Paclitaxel overview
Paclitaxel (FID-007) is under development for the treatment of non-small cell lung cancer, breast cancer, pancreatic cancer, head and neck cancer, bile duct cancer, recurrent head and neck cancer squamous cell carcinoma, paranasal sinuses and nasal cavity cancer, nasopharyngeal cancer, oropharyngeal cancer, oral cavity cancer, hypopharyngeal cancer and laryngeal cancer. It is administered through intravenous route. The drug candidate acts by targeting tubulin. It is developed based on nanoencapsulation technology. It was also under development for the treatment of leukemia, gastric cancer, ovarian cancer and bladder cancer.
Fulgent Pharma overview
Fulgent Pharma is a pharmaceutical company focusing on developing and commercializing innovative cancer therapeutics. The company is headquartered in Temple City, California, United States.
For a complete picture of Paclitaxel’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.